Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion
Open Access
- 24 May 2017
- journal article
- research article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 118 (6) , 883-891
Abstract
Background: In our preliminary study, the modified Marsh (M-Marsh) model caused an inadvertent underdosing of propofol in underweight patients. However, the predictive performance of the M-Marsh and Schnider models incorporated in commercially available target-controlled infusion (TCI) pumps was not evaluated in underweight patients. Methods: Thirty underweight patients undergoing elective surgery were randomly allocated to receive propofol via TCI using the M-Marsh or Schnider models. The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml−1. Arterial blood samples were obtained at least 7 min after achieving each pseudo-steady-state. Results: A total of 172 plasma samples were used to determine the predictive performance of both models. The pooled median (95% confidence interval) biases and inaccuracies at a target Ce ≤ 3 μg ml−1 were −22.6 (−28.8 to −12.6) and 31.9 (24.8–36.8) for the M-Marsh model and 9.0 (1.7–16.4) and 28.5 (21.7–32.8) for the Schnider model, respectively. These values at Ce ≥ 4 μg ml−1 were −9.6 (−16.0 to −6.0) and 24.7 (21.1–27.9) for the M-Marsh model and 19.8 (12.9–25.7) and 36.2 (31.4–39.7) for the Schnider model, respectively. Conclusions: The pooled biases and inaccuracies of both models were clinically acceptable. However, the M-Marsh and Schnider models consistently produced negatively and positively biased predictions, respectively, in underweight patients. In particular, the M-Marsh model showed greater inaccuracy at target Ce ≤ 3 μg ml−1 and the Schnider model showed greater inaccuracy at target Ce ≥ 4 μg ml−1. Therefore, it is necessary to develop a new pharmacokinetic model for propofol in underweight patients. Clinical trial registration: KCT0001502.Keywords
This publication has 29 references indexed in Scilit:
- External validation of pharmacokinetic and pharmacodynamic models of microemulsion and long-chain triglyceride emulsion propofol in beagle dogsJournal of Veterinary Pharmacology and Therapeutics, 2011
- Impact of Body Mass Index on Perioperative Outcomes in Patients Undergoing Major Intra-abdominal Cancer SurgeryAnnals of Surgical Oncology, 2008
- Malabsorption is a major contributor to underweight in Crohn’s disease patients in remissionNutrition, 2006
- Socioeconomic, psychosocial, behavioural, and psychological determinants of BMI among young women: differing patterns for underweight and overweight/obesityEuropean Journal of Public Health, 2005
- Pharmacokinetic Considerations in the Treatment of Inflammatory Bowel DiseaseClinical Pharmacokinetics, 2001
- Evaluation of the predictive performance of a ‘Diprifusor’ TCI systemAnaesthesia, 1998
- Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of RemifentanilAnesthesiology, 1997
- Pharmacokinetic Model Selection for Target Controlled Infusions of PropofolAnesthesiology, 1995
- Measuring the predictive performance of computer-controlled infusion pumpsJournal of Pharmacokinetics and Biopharmaceutics, 1992
- Total intravenous anaesthesia with propofol and alfentanil by computer‐assisted infusionAnaesthesia, 1988